Skip to main content

Table 2 Patients in remission at 12 months according to DAS28 and to modified ARA criteria.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Baseline status

Patients in DAS28 remission, n (%)

Patients in modified ARA remission, n (%)

DAS28

BIOL (n = 775)

CON (n = 255)

BIOL (n = 764)

CON (n = 256)

>3.2 to 4.0

16 (45.7)

8 (33.3)

9 (26.5)

4 (16.0)

>4.0 to 5.1

33 (26.4)

16 (23.2)

18 (14.3)

10 (14.5)

>5.1 to 6.0

40 (22.1)

10 (13.5)

38 (20.9)

8 (10.8)

>6.0 to 7.0

28 (11.1)

4 (6.3)

25 (10.1)

3 (4.8)

> 7.0

9 (5.0)

1 (4.0)

11 (6.3)

1 (3.8)

Total

126 (16.3)

39 (15.3)

101 (13.2)

26 (10.2)

  1. ARA, American Rheumatology Association; BIOL, patients treated with biologics; CON, patients receiving conventional DMARD treatment (control group); DAS28, disease activity score based on 28 joint counts.